Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 6/20 | 0.64 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | FPR1 | P21462 | 7/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434379 | 1.00 | FPR2 (0.64) | FPR2KDM1AFPR1MAOAMAOB | |
| SCHEMBL18579159 | 1.00 | FPR2 (0.64) | FPR2KDM1AFPR1MAOAMAOB | |
| SCHEMBL19559401 | 0.89 | FPR2 (0.65) | FPR2KDM1AFPR1MAOAMAOB | |
| SCHEMBL18117740 | 0.89 | FPR2 (0.65) | FPR2KDM1AFPR1MAOAMAOB | |
| SCHEMBL20041857 | 0.89 | FPR2 (0.65) | FPR2KDM1AFPR1MAOAMAOB | |
| SCHEMBL16785327 | 0.89 | FPR2 (0.65) | FPR2KDM1AFPR1MAOAMAOB | |
| SCHEMBL18106556 | 0.88 | FPR2 (0.51) | FPR2KDM1AFPR1MAOAMAOB | |
| SCHEMBL18106558 | 0.88 | FPR2 (0.51) | FPR2KDM1AFPR1MAOAMAOB | |
| SCHEMBL20041789 | 0.83 | FPR2 (0.49) | FPR2KDM1AFPR1MAOAMAOB | |
| SCHEMBL22166705 | 0.83 | FPR2 (0.49) | FPR2KDM1AFPR1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261155-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2022-03-01 | — | — | US | disclosed |
| US-20210107869-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | KYORIN SEIYAKU KK (JP) | 2021-04-15 | — | — | US | disclosed |
| US-20210107869-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | KYORIN SEIYAKU KK (JP) | 2021-04-15 | — | — | US | disclosed |
| US-10696630-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| CN-105814019-B | Urea derivative or pharmacologically acceptable salt thereof | 杏林制药株式会社 | 2019-12-06 | — | — | CN | disclosed |
| US-10464891-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| US-20190161445-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | KYORIN SEIYAKU KK (JP) | 2019-05-30 | — | — | US | disclosed |
| US-10252992-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2019-04-09 | — | — | US | disclosed |
| US-10029983-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-24 | — | — | US | disclosed |
| US-10029983-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20180044290-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN SEIYAKU KK (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9822069-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2017-11-21 | — | — | US | disclosed |
| US-9822069-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2017-11-21 | — | — | US | disclosed |
| EP-3075726-B1 | UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FORMYL PEPTIDE RECEPTOR LIKE 1 (FPRL-1) AGONISTS | KYORIN SEIYAKU KK (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-20170066718-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066718-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696630-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | FPR2 2/4885KDM1A 4486/4885FPR1 1/4885 |
| US-10464891-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | FPR2 2/4885KDM1A 4486/4885FPR1 1/4885 |
| US-20210107869-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | FPR1, FPR2, FPR3 | FPR2 2/4885KDM1A 4486/4885FPR1 1/4885 |
| US-10029983-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | FPR2 2/4885KDM1A 4486/4885FPR1 1/4885 |
| US-20170066718-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, FPR3 | FPR2 2/4885KDM1A 4486/4885FPR1 1/4885 |
| US-20190161445-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | FPR1, FPR2, FPR3 | FPR2 2/4885KDM1A 4486/4885FPR1 1/4885 |
| US-20180044290-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, FPR3 | FPR2 2/4885KDM1A 4486/4885FPR1 1/4885 |
| US-10252992-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | FPR2 2/4885KDM1A 4486/4885FPR1 1/4885 |
| US-11261155-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | FPR2 2/4885KDM1A 4486/4885FPR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.